Suven Life Sciences reported its results for the quarter ended June 30, 2018. The company’s standalone revenue for the quarter came in at Rs. 191.66 crore, registering 35.9 per cent yoy increase. This was mainly driven by a jump in revenue from the manufacturing segment by 35.2 per cent yoy.

Lira, the currency of Turkey, has fallen by 40 per cent the year till date with a fear of contagion being spread to other emerging countries including India.

 The company has an order book of more than Rs. 80,000 crore in hand. This leads to book/bill ratio of 13x which is highest amongst infrastructure companies.

The stock of pharma major Dr. Reddy's Laboratories was buzzing on Thursday as market expected the company to receive US drug regulator's approval for blockbuster cancer drug imatinib mesylate.

Double-digit returns in the longer term is what most mutual fund investors desire for. Mutual fund investments are meant for the long-term wealth creation and investors usually invest in the schemes for achieving long-term financial goals.

Sun Pharmaceutical Industries Limited has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the US Food and Drug Administration (FDA). CEQUA is indicated to increase the tear production in patients that suffer from the condition of Keratoconjunctivitis sicca that is, dry eyes.

Road and infrastructure builder, KNR Construction may sell four of its HAM (Hybrid Annuity Model) projects, reported a leading business daily. The company is said to be in talks with private equity firm Brookfield and Cube Highway for the deal.

Following stocks are close to their 52-week low as at 12.40 p.m. on August 16, 2018.

The markets on August 16, 2018 opened down. BSE Sensex is trading at 37,815.08, down by 36.92 points and the Nifty is trading at 11,422.90, down by 12.20 points. 

During the quarter, the company won new orders amounting to Rs. 2,744.1 crore. The net order book as on June 30 stood at Rs. 24,090.3 crore.